
COVIDã«ããããã¯ããŠã³äžãåã©ãã®èŠåã¯2åã®éãã§æªåãã
å èšäºã¯ãã¡ããã/Click here to read the original article.
仿ãBritish Journal of Ophthalmologyãèªã«çºè¡šãããç ç©¶ã®èè ãã¯ãåäŸãã¡ã®ãªã³ã©ã€ã³åŠç¿ãæžããããåŒã³ãããã
ã·ã«ãŽå°åã®åäŸãã¡ã®è¿èŠé²è¡çã¯ãCOVID-19ã®ããã¯ããŠã³æéäžã«ãããã¯ããŠã³åã®1幎éã®åãåäŸãã¡ã«æ¯ã¹ãŠ2å以äžã«å¢å ããããšããå°éå®¶ã®æ»èªãåããæ°ããç ç©¶ã§æããã«ãªã£ãã
ç±³åœçŒç§åŠäŒã«ãããšãè¿èŠã¯åäŸãã¡ã®éã§ãŸããŸãäžè¬çã«ãªã£ãŠãããæšèšã¯æ§ã ã ãã2050幎ãŸã§ã«äžç人å£ã®åæ°è¿ããè¿èŠã«ãªããšäºæ³ãããŠããã
11æ18æ¥ã«British Journal of Ophthalmologyèªã«çºè¡šãããç ç©¶èè ãã¯ã2019幎1æãã2021幎3æãŸã§ã®ã·ã«ãŽå°åã®2æ³ãã17æ³ã®åäŸ2,064人ã®çŒç§æ€æ»çµæã調ã¹ãã
圌ãã¯ãCOVID-19ããã¯ããŠã³åã®2019幎ãã2020å¹Žã®æ€æ»çµæã®éããšãCOVID-19ããã¯ããŠã³ãæœè¡ããã2020幎ãã2021å¹Žã®æ€æ»çµæã®éããæ¯èŒããã
çµ±èšåæã«ããã圌ã㯠ãCOVID-19ã®æµè¡æéäžã®èªå® ç£çŠãšãªã³ã©ã€ã³åŠç¿ã®æéã« ãè¿èŠã®é²è¡ã ãå€§å¹ ã«æªåããŠãã ãããšãçºèŠããã
å ·äœçã«ã¯ã2020幎ãã2021幎ã®è¿èŠé²è¡çã®å€åã¯ã2019幎ãã2020幎ã®å€åã®2å以äžïŒ2.2åïŒã§ãã£ãã
ãè¿èŠæç çã®æå€§ã®å¢å ã¯ãå°åŠæ ¡äœåŠå¹Žãç¹ã«8æ³å ããŸã17æ³å ã«ã¿ãããŸãã "ãšåœŒãã¯è¿°ã¹ãŠããã
èè ãã¯ããã®èª¿æ»çµæã¯ã宀å ã§æ¬ãèªãã ãã¹ã¯ãªãŒã³ãèŠããããæéãé·ãåäŸã¯èŠåãæªåããåŸåãããããšã瀺ãå è¡ç ç©¶ãšäžèŽããŠãããšè¿°ã¹ãŠããããŸããå±å€ã§éããããšãäžè¬çã«è¿èŠãäºé²ã»ç·©åããããšã瀺ãå è¡ç ç©¶ãåŒçšããŠããã
ç ç©¶è ãã¯ãCOVID-19ã®æµè¡æ¿çïŒåŠæ ¡ééãå±å€ã§ã®å£äœã¹ããŒãã®äžæ¢ãªã©ïŒããè¿èŠé²è¡ã®äžæã«äžåœ¹è²·ã£ãŠããå¯èœæ§ãé«ããšçµè«ã¥ããã
COVID-19ã®ééãçµãã£ãã«ããããããããªã³ã©ã€ã³åŠç¿æ³ããããŠã¹ã¯ãªãŒã³äœ¿çšæéã®å¢å ãå±å€ã§ã®æéã®æžå°ãç¶ããŠãããšããããã®ããšã¯ãåäŸã®ç®ã®å¥åº·ã«ãšã£ãŠåé¡ã§ããããšã瀺åããŠããã
ãã®ç ç©¶ã®èè ã¯ãåäŸãã¡ã®ãªã³ã©ã€ã³åŠç¿ãæžããããåŒã³ãããŠããã
8æ³ãš17æ³ãæå€§ã®äŒžã³ã瀺ãã
æ°ããªç ç©¶ã¯ãããã¯ããŠã³ãåäŸã10代ã®è¥è ã«å®³ãäžãããšããè°è«ã«éã¿ãå ãããã®ã§ããã9æãã¯ã·ã³ãã³å€§åŠã®ç ç©¶è ãã¡ã¯ãCOVID-19ããã¯ããŠã³ããã£ãŒã³ãšã€ãžã£ãŒã®è³ã®èåãä¿é²ããããšãçºèŠããã
ä»åã®æ°ããç ç©¶ã§ã¯ãããŒã¹ãŠã§ã¹ã¿ã³å€§åŠãã¡ã€ã³ããŒã°å»åŠéšãšã·ã«ãŽã®ã¢ã³ïŒãããŒãã»Hã»ã«ãŒãªãŒå°å ç é¢ã®ç ç©¶è ãã¡ããããã¯ããŠã³ãåäŸãã¡ã10代ã®è¥è ãã¡ã®èŠåã«ã©ã®ãããªåœ±é¿ãäžãããã調ã¹ãã
圌ãã¯ã2019幎ã2020幎ã2021幎ã«äžæ¬¡å°å ç é¢ã§ãµã€ã¯ããã¬ã°å±ææ€æ»ïŒçŒçãåŒç·©ãããç¹çŒè¬ãçšããèŠåæ€æ»ïŒãåããã·ã«ãŽå°åã®åäŸãš10代ã®è¥è ãã¡ã®ããŒã¿ã調ã¹ãã
圌ãã¯ãééæéäžã«åã©ããã¡ã®è¿èŠã®é²è¡ã亢é²ãããã©ããã調ã¹ãæ¹æ³ãšããŠããããã®å¹Žã®æ€æ»çµæã®éããæ¯èŒããã
ç ç©¶ããŒã ã¯æ¬¡ã®ããã«èª¬æããïŒ
ã2021幎ã®1æã2æã3æã«è¡ãããæ€æ»ã¯ã2020幎3æ17æ¥ã«åžå šäœã®å ¬ç«åŠæ ¡ééãå§ãŸã£ãŠä»¥æ¥ãå°å éå£ãé éåŠç¿ãçµéšããåŸã«è¡ãããã
ã2019幎ãš2020幎ã®1æã2æã3æã®æ€æ»ã¯ãCOVID-19ãã³ãããã¯ã«ããçæŽ»ç¿æ £ã®å€§ããªå€åãèµ·ããåã®ããŒã¿ãåæ ããŠããã
ããããã£ãŠã2019幎ãš2020幎ã®åæã«å蚺ããæ£è ã¯ãå¯Ÿç §ãæ£è ãšãªãã2021幎ã®åãåæã«å蚺ããæ£è ã¯ãè¡åå€å®¹å®éšãæ£è ãšãªããã
圌ãã¯ã2020幎ãã2021幎ã«ãããŠã®è¿èŠã®å¢å çã¯ã2019幎ãã2020幎ã«ãããŠã®å¢å çã®2å以äžã§ããããšãçºèŠããã
2020幎ãã2021幎ã«ãããŠã8æ³ãš17æ³ã®åäŸãæãå¢å ããïŒ25ïŒ ïŒã
ãã®å¢å ã¯ãCOVID-19ã®ããã¯ããŠã³ã®å幎ã䞡幎霢ã§è¿èŠãæžå°ããã®ãšã¯å¯Ÿç §çã§ãã£ããšããã2019幎ãã2020幎ã«ãããŠã8æ³ã¯1ïŒ æžå°ãã17æ³ã¯24ïŒ æžå°ããã
ããã«ã2019幎ã«ãã§ã«è¿èŠã§ãã£ãåäŸãã¡ã¯ãéåžžãèŠåã®æãæªåãå ±åããåäŸãã¡ã§ãã£ãã
ãã®ç ç©¶ã®èè ãã¡ã¯ãæè²ã¬ãã«å¥ã«åäŸãã¡ã®æ€æ»çµæãæ¯èŒãããå°åŠçãšäžåŠçãšé«æ ¡çã®è¿èŠæç çãæ¯èŒããã®ã§ããã
å°åŠçã¬ãã«ã®åäŸãã¡ã¯ãCOVID-19ã®ããã¯ããŠã³æéäžã«è¿èŠçãæãå¢å ããïŒ10ïŒ ïŒã
ããããèè ãã¯ããªã¹ã¯ãããã®ã¯å¹ŒãåäŸãã¡ã ãã§ã¯ãªããšææããŠãããã2021幎ã®17æ³ã«ãããè¿èŠæç çã®é¡èãªå¢å ã¯ãäºæ³å€ã®çºèŠã§ããã
圌ãã®ããŒã¿ã¯ã幎å°ã®åäŸãã¡ã ãã§ãªãã幎é·ã®åäŸãã¡ãææ¥æã®åäŸãã¡ã«å¯ŸããŠããã¹ã¯ãªãŒã³æéãæžãããå±å€ã§ã®æŽ»åãå¢ããããšãéèŠã§ããããšã瀺åããŠããã
ãŸããã¹ã¯ãªãŒã³æéã®å¢å ãå±å€æŽ»åã®æžå°ãåäŸã®èŠåã«åãŒãé·æçãªåœ±é¿ã«ã€ããŠããããªãç ç©¶ãå¿ èŠã§ãããšããŠããã
ç ç©¶èè ãã¯ããã®ç ç©¶ã®éçãšããŠãã¹ã¯ãªãŒã³ã¿ã€ã æéãšå±å€æŽ»åæéã®æ£ç¢ºãªæž¬å®ãæ¬ ããŠããããšãææããŠããã
ãã®ä»£ããã«èè ãã¯ãå ¬åŒã®æè²ã¬ã€ãã©ã€ã³ã®æé軞ãçšããŠãåäŸãã¡ã察é¢åŠç¿ãšéåžžã®å±å€æŽ»åããããªã³ã©ã€ã³åŠç¿ãšå¶éãããå±å€æŽ»åã«ã©ã®çšåºŠç§»è¡ããããæšæž¬ããã
ãçŽæ¥çãªæž¬å®ãã§ããªã以äžãæã ã®è§£éãšçµè«ã¯æ éã«ãªãããã¹ããã®ã§ããã
ãã®ç ç©¶ã¯ãéå¶å©å£äœResearch to Prevent Blindnessããã®å©æéã«ãã£ãŠè¡ãããã
DefenderãçŽã¯ãã®ç ç©¶ã®è²¬ä»»èè ã«é£çµ¡ãåã£ãããæéãŸã§ã«åçã¯åŸãããªãã£ãã